Page last updated: 2024-12-07

sr 33557

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fantofarone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119349
CHEMBL ID285855
SCHEMBL ID77818
MeSH IDM0166513

Synonyms (35)

Synonym
fantofarone
sr-33557
1-((p-(3-((3,4-dimethoxyphenethyl)methylamino)propoxy)phenyl)sulfonyl)-2-isopropylindolizine
fantofaronum [inn-latin]
fantofarona [inn-spanish]
benzeneethanamine, 3,4-dimethoxy-n-methyl-n-(3-(4-((2-(1-methylethyl)-1-indolizinyl)sulfonyl)phenoxy)propyl)-
3,4-dimethoxy-n-methyl-n-(3-(4-((2-(1-methylethyl)-1-indolizinyl)sulfonyl)phenoxy)propyl)benzeneethanmine
sr 33557
CHEMBL285855
bdbm50101905
n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methyl-3-[4-(2-propan-2-ylindolizin-1-yl)sulfonylphenoxy]propan-1-amine
fantofaronum
fantofarona
unii-ku213xyo69
114432-13-2
ku213xyo69 ,
fantofarone [inn:ban]
fantofarone [mi]
fantofarone [inn]
SCHEMBL77818
DTXSID30150729
sr33557
HY-105117
CS-0025047
benzeneethanamine, 3,4-dimethoxy-n-methyl-n-[3-[4-[[2-(1-methylethyl)-1-indolizinyl]sulfonyl]phenoxy]propyl]-
Q5434391
BCP29553
sr 33557; sr-33557; sr33557
n-(3,4-dimethoxyphenethyl)-3-(4-((2-isopropylindolizin-1-yl)sulfonyl)phenoxy)-n-methylpropan-1-amine
n-(3,4-dimethoxyphenethyl)-3-(4-(2-isopropylindolizin-1-ylsulfonyl)phenoxy)-n-methylpropan-1-amine
EX-A1900
D93346
AS-56270
AKOS037515619
AC-35860

Research Excerpts

Overview

SR 33557 is a new calcium channel blocker belonging to the chemical class of indolizinsulfones (IC50 = 0.6 nM, 3H-nitrendipine). In vitro demonstrated selectivity for smooth muscle over cardiac muscle.

ExcerptReferenceRelevance
"SR 33557 is a new calcium antagonist which in vitro demonstrated selectivity for smooth muscle over cardiac muscle. "( Hemodynamic effects of a new calcium antagonist, SR 33557, in patients with coronary artery disease and normal left ventricular function.
Castaigne, A; Dubois-Randé, JL; Habbal, R; Lellouche, D; Saal, JP; Sissmann, J, 1994
)
1.99
"SR 33557 (SR) is a new calcium channel blocker belonging to the chemical class of indolizinsulfones (IC50 = 0.6 nM, 3H-nitrendipine). "( [Hypotensive effect of a new calcium antagonist, SR 33557 in conscious rats].
Canals, F; Chatelain, P; Galindo, G; Lacour, C; Nisato, D, 1990
)
1.98

Effects

SR 33557 has been shown to bind with high affinity (Kd congruent to 0.36 nM, calculated from saturation isotherms and association/dissociation kinetics) to a single class of sites in a purified preparation of rat cardiac sarcolemmal membranes.

ExcerptReferenceRelevance
"SR 33557 has negative chronotropic action but shows no direct negative inotropic effect in patients with normal systolic LV function."( Hemodynamic effects of a new calcium antagonist, SR 33557, in patients with coronary artery disease and normal left ventricular function.
Castaigne, A; Dubois-Randé, JL; Habbal, R; Lellouche, D; Saal, JP; Sissmann, J, 1994
)
1.26
"[3H]SR 33557 has been shown to bind with high affinity (Kd congruent to 0.36 nM, calculated from saturation isotherms and association/dissociation kinetics) to a single class of sites in a purified preparation of rat cardiac sarcolemmal membranes."( Characterization of the slow calcium channel binding sites for [3H]SR 33557 in rat heart sarcolemmal membranes.
Beaufort, P; Chatelain, P; Clinet, M; Meysmans, L, 1991
)
1

Toxicity

ExcerptReferenceRelevance
" In doses of 100 mg to 150 mg twice daily, monotherapy fantofarone was effective and safe in the treatment of patients with chronic, stable angina pectoris."( Safety and efficacy of monotherapy with fantofarone, a novel calcium channel antagonist, in patients with chronic stable angina pectoris. Fantofarone Study Group.
Glasser, SP; Humen, DP; Singh, SN, 1997
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
"To investigate the pharmacokinetics of SR 33671, the main active metabolite of the calcium antagonist fantofarone, and the relationships between its concentrations and pharmacodynamic effects after a single oral administration of two doses (100 and 300 mg) of fantofarone."( Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers.
Bellissant, E; Giudicelli, JF, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID78491Inhibitory concentration of [3H]- nitrendipine binding against guinea pig cerebral cortex membrane1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Novel heterocyclic analogues of the new potent class of calcium entry blockers: 1-[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1207705Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1207704Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID195197Inhibition of [Ca2+] induced contraction of K+ depolarized rat aorta by 50%1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Novel heterocyclic analogues of the new potent class of calcium entry blockers: 1-[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID76235Displacement of [3H]nitrendipine binding to L-type calcium channel of Guinea pig cerebral cortex membranes1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel class of calcium-entry blockers: the 1[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID180478Molar concentration required to block [Ca2+] induced contraction of K+ depolarized rat aorta by 50%1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
A novel class of calcium-entry blockers: the 1[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.13)18.7374
1990's39 (82.98)18.2507
2000's6 (12.77)29.6817
2010's1 (2.13)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index6.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (6.00%)5.53%
Reviews1 (2.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other46 (92.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]